Albireo Pharma Inc company profile

Arvid Wallgrens Backe 20

Gothenburg, 413 46

46 3 17 41 14 80


Albireo AB, a biotechnology company, focuses on the development of therapeutic drugs for gastrointestinal and liver diseases. Its pipeline programs include Elobixibat IBAT inhibitor for IBS-C and chronic constipation; A4250 IBAT inhibitor for cholestatic liver diseases; A3384 for bile acid mal-absorption; locally active PPAR agonists for IBD; IBAT inhibitor for type 2 diabetes and mellitus; and A3914 and A5425 NK antagonist for atopic dermatitis and psoriasis post-operative adhesions. Albireo AB was founded in 2008 and is based in Gothenburg, Sweden.As on November 3, 2016, Albireo Pharma, Inc. went public through a reverse merger with Biodel Inc

Proudly made at